

FDA Provides 510(k) Clearance For BAUSCH + LOMB INFUSE™ Daily Disposable Silicone Hydrogel (SiHy Daily) Contact Lenses

June 04, 2020

BRIDGEWATER, N.J., June 4, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for BAUSCH + LOMB INFUSE™ daily disposable silicone hydrogel (SiHy daily) contact lenses.

BAUSCH + LOMB INFUSE contact lenses feature a next generation contact lens material (kalifilcon A), which is designed to meet the unmet needs of contact lens wearers, including those who experience contact lens dryness. Engineered with Bausch + Lomb's most advanced proprietary contact lens technologies, BAUSCH + LOMB INFUSE offers outstanding breathability for healthy lens wear while providing exceptional all-day comfort and high definition optics.

"Bausch + Lomb continues to push the innovation curve in the contact lens space with the FDA's clearance of BAUSCH + LOMB INFUSE," said Joe Gordon, U.S. president, Bausch + Lomb. "We are excited to add this breakthrough new SiHy daily contact lens to our portfolio and provide the outstanding health, vision and comfort that practitioners expect and patients deserve from Bausch + Lomb. We anticipate BAUSCH + LOMB INFUSE will be available to eye care practitioners in the second half of 2020."

About Bausch + Lomb

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit

www.bausch.com

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at

www.bauschhealth.com

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words

"anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes,"

"estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

®/TM are trademarks of Bausch & Lomb Incorporated or its affiliates.

© 2020 Bausch & Lomb Incorporated or its affiliates.

INF.0043.USA.20

Investor Contact:

Arthur Shannon

arthur.shannon@bauschhealth.com

(514) 856-3855

(877) 281-6642 (toll free)

Media Contact:

Lainie Keller

lainie.keller@bauschhealth.com

(908) 927-1198





View original content to download multimedia:

<http://www.prnewswire.com/news-releases/fda-provides-510k-clearance-for-bausch--lomb-infuse-daily-disposable-silicone-hydrogel-sihy-daily-contact-lenses-301070542.html>

SOURCE Bausch Health Companies Inc.



Investor Inquiries

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

LEGAL NOTICE

PRIVACY POLICY

EMAIL ALERTS

EMAIL PAGE

RSS FEED

Use of this site signifies your agreement to
the Legal Notice and Privacy Policy.
©2025 Bausch Health Companies Inc. All rights
reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY
PERSONAL INFORMATION**

